Sellas Life Sciences Group (SLS) is presented as a high-conviction buy due to its potential in AML treatment, upcoming catalysts, and significant short squeeze potential.
Source Post
Is Sellas Life Sciences Group Inc SLS A Good Time To Buy Now? SLS Stock Analysis
Mar 15, 2026
This analysis of Sellas Life Sciences Group (SLS) highlights a pre-revenue biotech company with a stock that has surged over 200% in six months, hitting a new 52-week high. The discussion delves into the company's flagship assets, GPS (a multipeptide vaccine) and SLS009 (a CDK9 inhibitor), both targeting relapsed and refractory Acute Myeloid Leukemia (AML). Despite significant cash burn and negative earnings, the market is pricing in future success, driven by potential FDA approval and a high short interest (over 27%) that could fuel a short squeeze. The analysis contrasts algorithmic skepticism with bullish analyst sentiment, setting a consensus price target of $7. Key catalysts include upcoming earnings and the critical Regal Phase 3 readout for GPS. The report outlines two investment strategies: a short-term swing trade capitalizing on volatility and a long-term hold betting on commercialization.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
SLSbuy opened Mar 15, 2026
+87.90%